Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL

Ahn, Jae Hyun; Lee, Jeong Zoo; Chung, Moon Kee; Ha, Hong Koo

doi:10.3346/jkms.2014.29.3.338

Cited by 16 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seo, et al 32 reported that the prostate cancer detection rate of Korean men with PSA levels under 10 ng/mL was 19.6%. Similarly, according to Ahn, et al, 33 the detection rate of our institute during the last 13 years was 21.8%. Even with variation in the study cohorts, or the presence of selection or sampling bias, the gap in detection rate between the present study and current literatures is substantial.…”

Section: Discussionsupporting

confidence: 72%

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL

et al. 2016

Self Cite

View full text Add to dashboard Cite

PurposeTo compare prostate cancer detection rates between 12 cores transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and visually estimated multiparametric magnetic resonance imaging (mp-MRI)-targeted prostate biopsy (MRI-visual-Bx) for patients with prostate specific antigen (PSA) level less than 10 ng/mL.Materials and MethodsIn total, 76 patients with PSA levels below 10 ng/mL underwent 3.0 Tesla mp-MRI and TRUS-Bx prospectively in 2014. In patients with abnormal lesions on mp-MRI, we performed additional MRI-visual-Bx. We compared pathologic results, including the rate of clinically significant prostate cancer cores (cancer length greater than 5 mm and/or any Gleason grade greater than 3 in the biopsy core).ResultsThe mean PSA was 6.43 ng/mL. In total, 48 of 76 (63.2%) patients had abnormal lesions on mp-MRI, and 116 targeted biopsy cores, an average of 2.42 per patient, were taken. The overall detection rates of prostate cancer using TRUS-Bx and MRI-visual-Bx were 26/76 (34.2%) and 23/48 (47.9%), respectively. In comparing the pathologic results of TRUS-Bx and MRI-visual-Bx cores, the positive rates were 8.4% (77 of 912 cores) and 46.6% (54 of 116 cores), respectively (p<0.001). Mean cancer core lengths and mean cancer core percentages were 3.2 mm and 24.5%, respectively, in TRUS-Bx and 6.3 mm and 45.4% in MRI-visual-Bx (p<0.001). In addition, Gleason score ≥7 was noted more frequently using MRI-visual-Bx (p=0.028). The detection rate of clinically significant prostate cancer was 27/77 (35.1%) and 40/54 (74.1%) for TRUS-Bx and MRI-visual-Bx, respectively (p<0.001).ConclusionMRI-visual-Bx showed better performance in the detection of clinically significant prostate cancer, compared to TRUS-Bx among patients with a PSA level less than 10 ng/mL.

show abstract

Section: Discussionsupporting

confidence: 72%

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…A nomogram is a graphical tool and can be used for anyone to a predict prevalence rate because it is calculated by adding points. It has been developed for many diseases studied in preventive medicine or diagnostic medicine (Ahn et al, 2014;Kattan et al, 1998;Kim et al, 2016). In this study, we introduced nomogram based on naïve Bayesian classifier model and applied it to CVD data from KN-HANES 2013-2015.…”

Section: Conclusion and Discussionmentioning

confidence: 99%

A novel nomogram of naïve Bayesian model for prevalence of cardiovascular disease

Kang

Kim

Lee

2018

CSAM

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide and has a high mortality rate after onset; therefore, the CVD management requires the development of treatment plans and the prediction of prevalence rates. In our study, age, income, education level, marriage status, diabetes, and obesity were identified as risk factors for CVD. Using these 6 factors, we proposed a nomogram based on a naïve Bayesian classifier model for CVD. The attributes for each factor were assigned point values between −100 and 100 by Bayes' theorem, and the negative or positive attributes for CVD were represented to the values. Additionally, the prevalence rate can be calculated even in cases with some missing attribute values. A receiver operation characteristic (ROC) curve and calibration plot verified the nomogram. Consequently, when the attribute values for these risk factors are known, the prevalence rate for CVD can be predicted using the proposed nomogram based on a naïve Bayesian classifier model.

show abstract

“…However, to the best of our knowledge, this study included the largest number of patients with PSA levels in the “gray zone” in a Chinese population. Second, other models that predict the risk of prostate cancer among men with PSA levels between 4 and 10 ng/ml exist [20] , [21] . Nevertheless, compared with other models, our model had a higher AUC (0.789 vs. 0.73 and 0.759 respectively) and higher predictive accuracy based on PSA alone (0.223 vs. 0.11 and 0.182 respectively), which indicated that our model is more reliable and could identify more patients with a high risk for prostate cancer as shown in Table 4 .…”

Section: Discussionmentioning

confidence: 99%

Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 ng/ml via a New Model to Reduce Unnecessary Prostate Biopsies

et al. 2014

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to develop a follow-up strategy based on the new model to reduce unnecessary prostate biopsies in patients with prostate specific antigen (PSA) ranging from 4 to 10 ng/ml.MethodsA total of 436 patients with PSA ranging from 4 to 10 ng/ml who had undergone transrectal ultrasound (TRUS)-guided prostate biopsy were evaluated during the first stage. Age, PSA, free PSA (fPSA), digital rectal examination (DRE) findings, ultrasonic hypoechoic mass, ultrasonic microcalcifications, prostate volume (PV) and PSA density (PSAD) were considered as predictive factors. A multiple logistic regression analysis involving a backward elimination selection procedure was applied to select independent predictors. After a comprehensive analysis of all results, we developed a new model to assess the risk of prostate cancer and an effective follow-up strategy.ResultsAge, PSA, PV, fPSA, rate of abnormal DRE findings and rate of hypoechoic masses detected by TRUS were included in our model. A significantly greater area under the receiver-operating characteristic curve was obtained in our model when compared with using PSA alone (0.782 vs. 0.566). Patients were grouped according to the value of prostate cancer risk (PCaR). In the second stage of our study, patients with PCaR>0.52 were recommended to undergo biopsies immediately while the rest of the patients continued close follow-up observation. Compared with the first stage, the detection rate of PCa in the second stage was significantly increased (33.0% vs 21.1%, p = 0.012). There was no significant difference between the two stages in distribution of the Gleason score (p = 0.808).ConclusionsWe developed a follow-up strategy based on the new model, which reduced unnecessary prostate biopsies without delaying patients’ diagnoses and treatments.

show abstract

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL

Cited by 16 publications

References 19 publications

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL

A novel nomogram of naïve Bayesian model for prevalence of cardiovascular disease

Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 ng/ml via a New Model to Reduce Unnecessary Prostate Biopsies

Contact Info

Product

Resources

About